Literature DB >> 24907382

Diminished systemic and antigen-specific type 1, type 17, and other proinflammatory cytokines in diabetic and prediabetic individuals with latent Mycobacterium tuberculosis infection.

Nathella Pavan Kumar1, Parakkal Jovvian George1, Paul Kumaran2, Chandra Kumar Dolla2, Thomas B Nutman3, Subash Babu4.   

Abstract

BACKGROUND: Diabetes mellitus type 2 (DM) is known to be a major risk factor for the development of active tuberculosis, although its influence on latent Mycobacterium tuberculosis infection (hereafter, "latent infection") remains poorly characterized.
METHODS: We examined circulating plasma cytokine levels in individuals with latent infection with DM or pre-DM (ie, intermediate hyperglycemia) and compared them to levels in patients with latent infection and normal glycemic control.
RESULTS: In persons with DM or pre-DM, latent infection is characterized by diminished circulating levels of type 1 (interferon γ, interleukin 2, and tumor necrosis factor α) and type 17 (interleukin 17F) cytokines. This was associated with decreased systemic levels of other proinflammatory cytokines (interleukin 1β and interleukin 18) and the antiinflammatory cytokine interleukin 10 but not with decreased systemic levels of type 2 cytokines. Moreover, latently infected individuals with DM had diminished levels of spontaneous and M. tuberculosis antigen-specific levels of type 1 and type 17 cytokines when antigen-stimulated whole blood was examined. Finally, there was no significant correlation between the levels of any of the cytokines measured (with the exception of interleukin 22) with hemoglobin A1c levels.
CONCLUSIONS: Our data reveal that latent infection in the presence of DM or pre-DM, is characterized by diminished production of cytokines, implicated in the control of M. tuberculosis activation, allowing for a potential immunological mechanism that could account for the increased risk of active tuberculosis in latently infected individuals with DM. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.

Entities:  

Keywords:  bacterial; cytokines; diabetes; pre-diabetes; tuberculosis

Mesh:

Substances:

Year:  2014        PMID: 24907382      PMCID: PMC4215076          DOI: 10.1093/infdis/jiu329

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  28 in total

1.  Standards of medical care in diabetes--2013.

Authors: 
Journal:  Diabetes Care       Date:  2013-01       Impact factor: 19.112

Review 2.  Diabetes and immunity to tuberculosis.

Authors:  Nuria Martinez; Hardy Kornfeld
Journal:  Eur J Immunol       Date:  2014-02-16       Impact factor: 5.532

Review 3.  Immune dysfunction in patients with diabetes mellitus (DM).

Authors:  S E Geerlings; A I Hoepelman
Journal:  FEMS Immunol Med Microbiol       Date:  1999-12

4.  A protective and agonistic function of IL-12p40 in mycobacterial infection.

Authors:  C Hölscher; R A Atkinson; B Arendse; N Brown; E Myburgh; G Alber; F Brombacher
Journal:  J Immunol       Date:  2001-12-15       Impact factor: 5.422

5.  Expansion of pathogen-specific T-helper 1 and T-helper 17 cells in pulmonary tuberculosis with coincident type 2 diabetes mellitus.

Authors:  Nathella Pavan Kumar; Rathinam Sridhar; Vaithilingam V Banurekha; Mohideen S Jawahar; Thomas B Nutman; Subash Babu
Journal:  J Infect Dis       Date:  2013-05-28       Impact factor: 5.226

6.  Type 2 diabetes mellitus coincident with pulmonary tuberculosis is associated with heightened systemic type 1, type 17, and other proinflammatory cytokines.

Authors:  Nathella Pavan Kumar; Rathinam Sridhar; Vaithilingam V Banurekha; Mohideen S Jawahar; Michael P Fay; Thomas B Nutman; Subash Babu
Journal:  Ann Am Thorac Soc       Date:  2013-10

Review 7.  Prediabetes: a high-risk state for diabetes development.

Authors:  Adam G Tabák; Christian Herder; Wolfgang Rathmann; Eric J Brunner; Mika Kivimäki
Journal:  Lancet       Date:  2012-06-09       Impact factor: 79.321

Review 8.  Host-pathogen interactions in tuberculosis patients with type 2 diabetes mellitus.

Authors:  Blanca I Restrepo; Larry S Schlesinger
Journal:  Tuberculosis (Edinb)       Date:  2013-12       Impact factor: 2.973

Review 9.  The immune response in tuberculosis.

Authors:  Anne O'Garra; Paul S Redford; Finlay W McNab; Chloe I Bloom; Robert J Wilkinson; Matthew P R Berry
Journal:  Annu Rev Immunol       Date:  2013       Impact factor: 28.527

10.  Plasma heme oxygenase-1 levels distinguish latent or successfully treated human tuberculosis from active disease.

Authors:  Bruno B Andrade; Nathella Pavan Kumar; Katrin D Mayer-Barber; Daniel L Barber; Rathinam Sridhar; Vaithilingam V Banu Rekha; Mohideen S Jawahar; Thomas B Nutman; Alan Sher; Subash Babu
Journal:  PLoS One       Date:  2013-05-06       Impact factor: 3.240

View more
  23 in total

1.  Building capacity for advances in tuberculosis research; proceedings of the third RePORT international meeting.

Authors:  Yuri F van der Heijden; Fareed Abdullah; Bruno B Andrade; Jason R Andrews; Devasahayam J Christopher; Julio Croda; Heather Ewing; David W Haas; Mark Hatherill; C Robert Horsburgh; Vidya Mave; Helder I Nakaya; Valeria Rolla; Sudha Srinivasan; Retna Indah Sugiyono; Cesar Ugarte-Gil; Carol Hamilton
Journal:  Tuberculosis (Edinb)       Date:  2018-10-01       Impact factor: 3.131

Review 2.  Diabetes and Tuberculosis.

Authors:  Blanca I Restrepo
Journal:  Microbiol Spectr       Date:  2016-12

3.  Impaired Cytokine but Enhanced Cytotoxic Marker Expression in Mycobacterium tuberculosis-Induced CD8+ T Cells in Individuals With Type 2 Diabetes and Latent Mycobacterium tuberculosis Infection.

Authors:  Nathella Pavan Kumar; Kadar Moideen; Parakkal Jovvian George; Chandrakumar Dolla; Paul Kumaran; Subash Babu
Journal:  J Infect Dis       Date:  2015-10-20       Impact factor: 5.226

4.  Adults with Mycobacterium tuberculosis infection and pre-diabetes have increased levels of QuantiFERON interferon-gamma responses.

Authors:  Matthew J Magee; Susanna L Trost; Argita D Salindri; Genet Amere; Cheryl L Day; Neel R Gandhi
Journal:  Tuberculosis (Edinb)       Date:  2020-04-02       Impact factor: 3.131

5.  Type 2 diabetes - Tuberculosis co-morbidity is associated with diminished circulating levels of IL-20 subfamily of cytokines.

Authors:  Nathella Pavan Kumar; Vaithilingam V Banurekha; Dina Nair; Paul Kumaran; Chandra Kumar Dolla; Subash Babu
Journal:  Tuberculosis (Edinb)       Date:  2015-08-28       Impact factor: 3.131

6.  Profiling leucocyte subsets in tuberculosis-diabetes co-morbidity.

Authors:  Nathella Pavan Kumar; Kadar Moideen; Sharmila D Dhakshinraj; Vaithilingam V Banurekha; Dina Nair; Chandrakumar Dolla; Paul Kumaran; Subash Babu
Journal:  Immunology       Date:  2015-07-06       Impact factor: 7.397

Review 7.  Influence of diabetes mellitus on immunity to human tuberculosis.

Authors:  Pavan Kumar Nathella; Subash Babu
Journal:  Immunology       Date:  2017-06-29       Impact factor: 7.397

8.  Mycobacterial Growth Inhibition Assay (MGIA) as a Host Directed Diagnostic Tool for the Evaluation of the Immune Response in Subjects Living With Type 2 Diabetes Mellitus.

Authors:  Miriam Bobadilla-Del-Valle; Francisco Leal-Vega; Pedro Torres-Gonzalez; Anabel Ordaz-Vazquez; Maria de Lourdes Garcia-Garcia; Ma de Los Angeles Tovar-Vargas; Guadalupe Delgado-Sanchez; Paola Del Carmen Guerra De Blas; Robert S Wallis; Alfredo Ponce-De-León; José Sifuentes-Osornio
Journal:  Front Cell Infect Microbiol       Date:  2021-05-18       Impact factor: 5.293

9.  Factors that Predict Negative Results of QuantiFERON-TB Gold In-Tube Test in Patients with Culture-Confirmed Tuberculosis: A Multicenter Retrospective Cohort Study.

Authors:  Yong-Soo Kwon; Yee Hyung Kim; Kyeongman Jeon; Byeong-Ho Jeong; Yon Ju Ryu; Jae Chol Choi; Ho Cheol Kim; Won-Jung Koh
Journal:  PLoS One       Date:  2015-06-12       Impact factor: 3.240

10.  Latent tuberculosis infection among patients with and without type-2 diabetes mellitus: results from a hospital case-control study in Atlanta.

Authors:  Argita D Salindri; J Sonya Haw; Genet A Amere; Joyce T Alese; Guillermo E Umpierrez; Matthew J Magee
Journal:  BMC Res Notes       Date:  2021-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.